Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Johnson Matthey (JMAT) by Jefferies
- Avoid Topps Tiles (TPT) by Steve Moore in ShareProphets
- Hold GSK (GSK) by Harvey Jones in The Motley Fool
- Buy W.A.G Payment Solutions (WPS) by UBS
- Neutral United Utilities Group (UU.) by Goldman Sachs
- Sell ITM Power (ITM) by Goldman Sachs
- Equal Weight Synthomer (SYNT) by Barclays
- Outperform Direct Line Insurance Group (DLG) by Exane
- Equal Weight SEGRO (SGRO) by Barclays
- Hold Boohoo Group (BOO) by Jefferies
- Neutral Diageo (DGE) by JP Morgan
- Underweight Haleon (HLN) by JP Morgan
- Neutral PZ Cussons (PZC) by JP Morgan
- Overweight Unilever (ULVR) by JP Morgan
- Neutral Reckitt Benckiser Group (RKT) by JP Morgan
- Neutral British American Tobacco (BATS) by JP Morgan
- Neutral Fevertree Drinks (FEVR) by JP Morgan
- Overweight Imperial Brands (IMB) by JP Morgan
- Neutral Coca-Cola Europacific Partners (DI) (CCEP) by JP Morgan
- Neutral Aston Martin Lagonda Global Holdings (AML) by JP Morgan
Nuformix (NFX) Share Price
Health Care Sector
NOTE: This is based on 8 open tips for Nuformix (NFX)
| Latest Bid : 0.04p | Latest Ask : 0.06p |
| High Today : 0.06p | Low Today : 0.05p |
| This Years High : 0.40p | This Years Low : 0.05p |
| Volume : 85,401,021 | MKT Cap : £0.71M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Nuformix (NFX) Overview
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. We use our expertise in discovering, developing and patenting novel drug forms with improved physical properties, to develop new products in new indications that are differentiated from the original by way of: dosage, delivery route or presentation, thus creating new and attractive commercial opportunities.Nuformix (NFX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Steve Moore | Premium Only | 2023-05-25 11:25:00 25/05/2023 | 76.14% |
| Sell | Steve Moore | Premium Only | 2023-05-22 14:35:00 22/05/2023 | 76.14% |
| Sell | Steve Moore | Premium Only | 2023-05-18 14:25:00 18/05/2023 | 77.17% |
| Sell | Steve Moore | Premium Only | 2023-04-17 14:40:00 17/04/2023 | 76.14% |
| Avoid | Steve Moore | Premium Only | 2022-12-13 14:00:00 13/12/2022 | 83.59% |
Nuformix (NFX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 0.04p | Latest Ask : 0.06p |
| High Today : 0.06p | Low Today : 0.05p |
| This Years High : 0.40p | This Years Low : 0.05p |
| Volume : 85,401,021 | MKT Cap : £0.71M |
Nuformix Overview
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. We use our expertise in discovering, developing and patenting novel drug forms with improved physical properties, to develop new products in new indications that are differentiated from the original by way of: dosage, delivery route or presentation, thus creating new and attractive commercial opportunities.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Nuformix Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Steve Moore | Premium Only | 2023-05-25 11:25:00 25/05/2023 | 76.14% |
| Sell | Steve Moore | Premium Only | 2023-05-22 14:35:00 22/05/2023 | 76.14% |
| Sell | Steve Moore | Premium Only | 2023-05-18 14:25:00 18/05/2023 | 77.17% |
| Sell | Steve Moore | Premium Only | 2023-04-17 14:40:00 17/04/2023 | 76.14% |
| Avoid | Steve Moore | Premium Only | 2022-12-13 14:00:00 13/12/2022 | 83.59% |